Patents by Inventor Ming F. Chan
Ming F. Chan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6258844Abstract: The invention relates to the use of omega chain modified prostaglandins as ocular hypotensive. The derivatives used in accordance with the invention are encompassed by the following structure formula I: wherein the hatched segments represent &agr; bonds; the wavy segment represents an &agr; or &bgr; bond; dashed lines represent a double bond or a single bond; X is selected from the group consisting of —OR and N(R2); Y is=O or represents 2 hydrogen radicals, provided that Y represents 2 hydrogen radicals when X is OH; R is hydrogen or a lower alkyl radical having up to six carbon atoms; R1 is=O or hydroxy; m is 0, 2, 4 or 6, provided that m is not 4 when the wavy segment represents a &bgr; bond; n is 0, 2, 4 or 6; x and y are 0 or 1, provided that x is 1 when y is 0 and y is 1 when x is 0; or 9, 11 and/or 15 ester derivatives of said compound of formula I, e.g. a C1 to C6 alkyl ester derivative; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 24, 1998Date of Patent: July 10, 2001Assignee: Allergan Sales, Inc.Inventors: Michael E. Garst, Michael B. Roof, Ming F. Chan, David F. Woodward, Robert M. Burk, Todd S. Gac, Steven W. Andrews
-
Patent number: 5767154Abstract: The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are encompassed by the following structure formula I: ##STR1## wherein wavy line attachments indicate either the alpha (a) or beta (b) configuration; hatched lines indicate a configuration, solid triangles are used to indicate b configuration, dashed bonds represent a double bond, or a single bond; n is 0, or an integer of from 1 to 3; X is NH.sub.2 or OR; R is hydrogen, R.sub.4 or a --(CO)R.sub.4 group; R.sub.1, R.sub.2, and R.sub.3 independently are hydroxyl, or --O(CO)R.sub.5 groups, wherein R.sub.4 and R.sub.5 independently stand for saturated or unsaturated acyclic hydrocarbon having from 1 to 20 carbon atoms, or --(CH.sub.2).sub.m R.sub.6 where m is 0-10 and R.sub.6 is an aliphatic, aromatic or heteroaromatic ring, R.sub.7 and R.sub.8 together are .dbd.Type: GrantFiled: March 24, 1997Date of Patent: June 16, 1998Assignee: AllerganInventors: David A. Woodward, Ming F. Chan
-
Patent number: 5594021Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: GrantFiled: June 6, 1995Date of Patent: January 14, 1997Assignee: Texas Biotechnology CorporationInventors: Ming F. Chan, Bore G. Raju, Adam Kois, Erik J. Verner, Chengde Wu, Rosario S. Castillo, Venkatachalapathi Yalamoori, Vitukudi N. Balaji
-
Patent number: 5591761Abstract: Thiophenyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, isoxazolyl-thiophenyl-sulfonamides, isoxazolyl-furyl-sulfonamides and isoxazolyl-pyrrolyl-sulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: GrantFiled: April 5, 1994Date of Patent: January 7, 1997Assignee: Texas Biotechnology CorporationInventors: Ming F. Chan, Bore G. Raju, Adam Kois, Erik J. Verner, Chengde Wu, Rosario S. Castillo, Venkatachalapathi Yalamoori, Vitukudi N. Balaji
-
Patent number: 5543521Abstract: Compounds of formula (I) and pharmaceutical compositions containing the compounds of formula (I): ##STR1## are provided. In formula (I): Ar is a substituted or unsubstituted aromatic or heterocyclic group; R is H or a substituted or unsubstituted straight or branched chain, cyclic or mixture of straight branched and cyclic alkyl, alkenyl, or alkynyl group having from 1-20 carbon atom; A is a functional group that bears a polar moiety; R.sub.1 is R, R--C=0, R substituted with one or more heteroatoms, a substituted or unsubstituted aryl group, or is aryl-(CH.sub.2).sub.n ; R.sub.2 is (CH.sub.2).sub.n, CHR, C(R).sub.2, COO, OCO, NHCO, CONH, SO, SO.sub.2 or NR; R.sub.3 and R.sub.4, which are the same or different or each may be absent, and are .dbd.O, H, O-aryl, OR, O-alkyl or alkyl, aryl, SR, S-aryl, NHR, NH-aryl, NR, or are other heteroaromatic groups; R.sub.5 is H, OH or R; E and F, which are the same or are different, are either N or (CH.sub.2).sub.Type: GrantFiled: January 12, 1994Date of Patent: August 6, 1996Assignee: Immunopharmaceutics, Inc.Inventors: Ming F. Chan, Vitukudi N. Balaji
-
Patent number: 5514691Abstract: N-(4-halo-isoxazolyl)sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(4-halo-3-isoxazolyl)sulfonamides and N-(4-halo-5-isoxazolyl)benzenesulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: GrantFiled: October 21, 1993Date of Patent: May 7, 1996Assignee: Immunopharmaceutics, Inc.Inventors: Ming F. Chan, Bore G. Raju, Rosario S. Castillo, Adam Kois, Chengde Wu, Yalamoori Venkatachalapathi, Erik J. Verner, Vitukudi N. Balaji
-
Patent number: 5468778Abstract: Intraocular pressure is lowered in the eye of a mammal by administration of a pharmaceutical composition containing as active ingredient a compound of the formula ##STR1## where the dotted line represents a bond or the absence of a bond, wavy lines connected to the olefinic bond represent cis or trans configuration about the olefinic bond; R.sub.1 represents H, or CO-R.sub.3 where R.sub.3 is lower alkyl of 1 to 6 carbons, carbocyclic aryl or heterocyclic aryl; or carbocyclic aryl or heteroaryl substituted lower alkyl group; R.sub.2 represents H or lower alkyl of 1 to 6 carbons, and n is an integer between 0 and 8.Type: GrantFiled: September 24, 1992Date of Patent: November 21, 1995Assignee: Allergan, Inc.Inventors: Michael E. Garst, Robert M. Burk, Ming F. Chan, Michael B. Roof
-
Patent number: 5464853Abstract: N-(5-isoxazolyl)biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(5-isoxazolyl)biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: GrantFiled: October 21, 1993Date of Patent: November 7, 1995Assignee: ImmunoPharmaceutics, Inc.Inventors: Ming F. Chan, Bore G. Raju, Rosario S. Castillo, Adam Kois, Chengde Wu, Vitukudi Balaji
-
Patent number: 5446041Abstract: Disclosed is an intraocular pressure reducing method and composition wherein 11-acyl prostaglandins are contained in a pharmaceutically acceptable excipient for topical application to the surface of the eye.Type: GrantFiled: October 10, 1990Date of Patent: August 29, 1995Assignee: Allergan, Inc.Inventors: Ming F. Chan, David F. Woodward
-
Patent number: 5332730Abstract: The present invention provides novel 2-aliphatic or arylaliphatic cyclopentane heptanoic and heptenoic acid derivatives including at least one azido substituent. In particular 2-aliphatic or arylaliphatic cyclopentane heptenyloic and cyclopentane heptanoic acids and esters thereof, substituted at the 3 and/or 5 position of the cyclopentane ring with radicals selected from the group consisting of hydroxy, azido and mixtures thereof, are disclosed. These azido compounds are useful as ocular hypotensives and are intermediates for the preparation of other compounds useful as ocular hypotensives.Type: GrantFiled: October 16, 1992Date of Patent: July 26, 1994Assignee: Allergan, Inc.Inventor: Ming F. Chan
-
Patent number: 5328933Abstract: The present invention relates to cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or arylaliphatic derivatives. In particular, heptenylnitrate and heptanylnitrate 2-aliphatic or arylaliphatic derivatives, substituted at the 3 and/or 5 position of the cyclopentane ring with radicals selected from the group consisting of hydroxy, alkylcarboxy and mixtures thereof, are disclosed. These compounds are useful as ocular hypotensives.Type: GrantFiled: October 28, 1992Date of Patent: July 12, 1994Assignee: Allergan, Inc.Inventor: Ming F. Chan
-
Patent number: 5312832Abstract: The present invention relates to 2-decarboxyl-2-acylthioalkyl prostaglandins that are potent ocular hypotentives, and are particularly suitable for the management of glaucoma.Type: GrantFiled: May 17, 1991Date of Patent: May 17, 1994Assignee: Allergan, Inc.Inventor: Ming F. Chan
-
Patent number: 5288754Abstract: The present invention provides a method of treating ocular hypertension which comprises applying to the eye an amount sufficient to treat ocular hypertension of a compound of formula (I) ##STR1## wherein the wavy line attachments indicate either alpha (.alpha.) or beta (.beta.) configuration; hatched lines indicate .alpha. configuration, solid triangles are used to indicate .beta. configuration; the dashed bonds represent a single bond or a double bond which can be in the cis or trans configuration; X is selected from the group consisting of O, NH, S and NR, where R is an aliphatic hydrocarbon group of about 1 to about 6 carbon atoms; Y is a polar functional group; one of R.sub.1 and R.sub.2 is .dbd.O, --OH or a --O(CO)R.sub.4 group, and the other one is --OH or a --O(CO)R.sub.4 group or R.sub.1 is .dbd.O and R.sub.2 is is H; R.sub.3 is --OH or --O(CO)R.sub.4, wherein R.sub.4 is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or --(CH.sub.2).sub.n R.sub.Type: GrantFiled: February 4, 1992Date of Patent: February 22, 1994Assignee: Allergan, Inc.Inventors: David F. Woodward, Ming F. Chan
-
Patent number: 5270049Abstract: The present invention concerns 2-decarboxyl-2-aminoalkyl derivatives of naturally occurring and synthetic prostaglandins, N-substituted derivatives, ester prodrugs and homologues of such compounds that are potent ocular hypotensives, and are particularly suitable for the management of glaucoma.Type: GrantFiled: November 9, 1990Date of Patent: December 14, 1993Assignee: Allergan, Inc.Inventors: Ming F. Chan, David F. Woodward
-
Patent number: 5238961Abstract: The invention relates to the use of alcohol derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are encompassed by the following structural formula (I) ##STR1## wherein wherein wavy line attachments indicate either the alpha (.alpha.) or beta (b) configuration; hatched lines indicate .alpha. configuration, solid triangles are used to indicate b configuration, dashed bonds represent a double bond, the 5,6-double bond being in cis-configuration, or a single bond; R is hydrogen or a --(CO)R.sub.4 group; R.sub.1, R.sub.2, and R.sub.3 independently are hydroxyl, or --O(CO)R.sub.5 groups, wherein R.sub.4 and R.sub.5 independently stand for saturated or unsaturated acyclic hydrocarbon having from 1 to 20 carbon atoms, or --(CH.sub.2).sub.n R.sub.6 where n is 0-10 and R.sub.6 is an aliphatic, aromatic or heteroaromatic ring, R.sub.7 and R.sub.8 independently are hydrogen or alkyl of one to 6 carbon atoms or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 14, 1990Date of Patent: August 24, 1993Assignee: Allergan, Inc.Inventors: David F. Woodward, Ming F. Chan
-
Patent number: 5139491Abstract: The present invention relates to 2-decarboxyl-2-alkoxyalkyl prostaglandins that are potent ocular hypotentives, and are particularly suitable for the management of glaucoma. Said 2-decarboxyl-2-alkoxyalkyl prostaglandins are compounds of the formula (I) ##STR1## wherein the wavy line attachments indicate either alpha (.alpha.) or beta (.beta.) configuration; hatched lines indicate .alpha. configuration; solid triangles are used to indicate .beta. configuration; the dashed bonds represent a single bond or a double bond which can be in the cis or trans configuration; R is an aliphatic hydrocarbon group having from 1 to about 6 carbon atoms; one of R.sub.1 and R.sub.2 is=O, --OH or a --O(CO)R.sub.6 group, and the other one is --OH or a --O(CO)R.sub.6 group or R.sub.1 is=O and R.sub.2 is H, R.sub.3 is --OH or --O(CO)R.sub.6 ; R.sub.4 and R.sub.5 independently are hydrogen or an aliphatic hydrocarbon group having from 1 to about 6 carbon atoms; R.sub.Type: GrantFiled: December 6, 1990Date of Patent: August 18, 1992Assignee: Allergan, Inc.Inventors: Ming F. Chan, David F. Woodward
-
Patent number: 5034413Abstract: Certain 9,11-diacyl prostaglandins and their use for lowering intraocular pressure are disclosed herein.Type: GrantFiled: September 18, 1990Date of Patent: July 23, 1991Assignee: Allergan, Inc.Inventors: Ming F. Chan, Charles Gluchowski, David F. Woodward
-
Patent number: 5028624Abstract: Disclosed is an intraocular pressure reducing method and composition wherein 9,15-diacyl prostaglandins are contained in a pharmaceutically acceptable excipient for topical application on the surface of the eye.Type: GrantFiled: September 18, 1990Date of Patent: July 2, 1991Assignee: Allergan, Inc.Inventors: Ming F. Chan, David F. Woodward
-
Patent number: 4994274Abstract: Compounds and their use for lowering intraocular pressure are disclosed herein.Type: GrantFiled: July 27, 1989Date of Patent: February 19, 1991Assignee: Allergan, Inc.Inventors: Ming F. Chan, David F. Woodward